enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
enGene Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
enGene Therapeutics's pe ratio was 0.2× on Nov 30, 2023.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Nov 30, 2023 | 0.2× | – |
See a number that looks wrong?